Evaluation of Salivary Level of miR-155 and IL-10 in Oral Lichen Planus Patients Before and After Treatment With Topical Corticosteroid

Evaluation of Salivary Levels of miR-155 and IL-10 in Oral Lichen Planus Patients Before and After Treatment With Topical Corticosteroid

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03871114

Enrollment

Registered

2019-03-12

Start date

2019-03-10

Completion date

2019-04-25

Last updated

2019-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Lichen Planus

Brief summary

Thirty patients will be recruited from the outpatient clinic of the faculty of dentistry.fifteen systemically healthy individuals with normal mucosa and fifteen atrophic/erosive oral lichen planus patients. Oral lichen planus patients will be treated with a topical steroid and miR-155 and IL-10 will be assessed in saliva before and after 4 weeks of topical steroids use

Interventions

DRUGTriamcinolone Acetonide in orabase

treatment of OLP with topical steroid

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients clinically and histopathologically diagnosed as having atrophic/erosive OLP. * Patients free from any other oral lesions * cooperative patients who agrees to take the supplied medications. * Patients who are systemically healthy

Exclusion criteria

* Patients suffering from any systemic disease. * Treatment with any systemic treatment such as systemic steroids, other immunosuppressive drugs or non-steroidal anti-inflammatory drugs at least eight weeks. * Treatment with any oral topical medications for at least four weeks prior to the study. * Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame	Description
Measurement of salivary levels of miR-155 in OLP before treatment	baseline	assessment of miR-155 in saliva of patients with OLP before treatment
Measurement of salivary levels of IL-10 in OLP before treatment	baseline	assessment of IL-10 in saliva of patients with OLP before treatment

Secondary

Measure	Time frame	Description
Measurement of salivary levels of miR-155 in OLP after treatment	4 weeks	assessment of miR-155 in saliva of patients with OLP after treatment
Measurement of salivary levels of IL-10 in OLP after treatment	4 weeks	assessment of IL-10 in saliva of patients with OLP after treatment

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026